Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (4470)	1/12/1998 12:43:00 PM
From: LoLoLoLita	Read Replies (2) \| Respond to of 23519

blank-- Congrats on getting your letter published. The reporter was just doing a job, probably had a tight deadline to meet, and was probably just following orders to cook up an I Told You So story. The fact that they had no such letter from Nina Ferrari or Leland Wilson means that Vivus has better things to do than getting into a pissing match with a Dow Jones company. Be grateful they published it, anyone reading it should know that they wouldn't have published it unless there was some basis to your complaint. BIG COMPANIES HATE TO ADMIT MISTAKES. Questions for the CPAs: How much is Vivus spending on advertising? So far they had the one-page targeted insert in JAMA, then, the targeted mailing of a video and dummy Muse to Primary Care Physicians (reported by Zebra), next, the Feb 1 direct-to-consumer campaign in print ads. (has anyone heard of any mention of TV ads?). I can't see all this costing less than $20 M. Is this capitalized (amortized over time), or is it expensed (charged to current quarter)? David

To: blankmind who wrote (4470)	1/15/1998 2:33:00 PM
From: Tunica Albuginea	Read Replies (1) \| Respond to of 23519

Blankmind, in regards to Barons/Goldstein and your letter.I think that Goldstein's assertions have already been answered by the over 100 Urologists who have published the MUSE studies on effectiveness. The fact that Barrons reporter does not wish to acknowledge this is testimony to me that there is something fishy going on, what with the big short interest and selective Barrons reporting on Vivus plus turn abouts by Padma N, etc. Time will tell. By the way Goldstein's lab in Boston is not the only one in the nation and there is fine work done in numerous other places.Barrons just wants to keep beating the same old drum. The down side on Vivus is actually 8 IMO, going back to 1995. I am sorprised that 1st call has Vivus down for $1.04 in 97 and 0.98 in 1998 !!! : they must not be reading this thread, gg. TA TA